MarketCap
Facebook
X
TelegramAerpio Pharmaceuticals, Inc. Total Assets 2011-2026 | ARPO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 44.9 M | 39.9 M | 64.1 M | 21 M | 4.01 K | 18.5 K | 5.26 K | 8.78 K | 8.11 K | 6.62 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.1 M | 4.01 K | 17 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
22 B | $ 95.5 | -3.88 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
222 M | $ 2.59 | -4.78 % | $ 494 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
Cardiff Oncology
CRDF
|
61.9 M | $ 1.61 | -2.42 % | $ 108 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Cue Biopharma
CUE
|
42.2 M | $ 34.94 | 17.05 % | $ 3.31 B | USA |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
435 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Editas Medicine
EDIT
|
187 M | $ 3.04 | 1.33 % | $ 270 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
35 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 44.42 | 0.57 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
474 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Galapagos NV
GLPG
|
3.41 B | $ 28.39 | -0.13 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.27 | 0.49 % | $ 6.83 B |  Spain |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.5 | 5.42 % | $ 5.76 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
38.8 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
21.1 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
ImmuCell Corporation
ICCC
|
42.5 M | $ 8.87 | 1.66 % | $ 80.1 M | USA |
 |
InflaRx N.V.
IFRX
|
55.2 M | $ 1.97 | -7.51 % | $ 152 M | Germany |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |